Clinical Trial

Efficacy of Dapagliflozin Versus Metformin in Polycystic Ovary Syndrome

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated October 22, 2024 (before its estimated January 2025 completion). Its status may not reflect the trial's current state.
Summary
In PCOS (Polycystic Ovary Syndrome), studies have found impaired incretin secretion and activity, particularly in overweight/obese individuals. Conflicting results exist regarding glucagon-like peptide-1(GLP-1) levels in PCOS patients, with studies reporting reduced, normal, or increased levels. Incretin-based therapy has been suggested as a potential treatment to reverse prediabetes risk by preserving β-cell function in patients with impaired fasting glucose(IFG and impaired glucose tolerance(IGT). The study aims to compare the efficacy of Dapagliflozin to Metformin for the treatment of non-diabetic patients with polycystic ovary syndrome (PCOS).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-08-26.
Status change: Not Yet Recruiting → Recruiting 2024-10-18
Trial Details
NCT Number NCT06576375
Lead Sponsor Future University in Egypt
Collaborators: October 6 University
Conditions Polycystic Ovary Syndrome
Enrollment 70 participants
Start Date 2024-09-02
Primary Completion 2025-01 (estimated)
Study Completion 2025-01 (estimated)
Updated on ClinicalTrials.gov 2024-10-22